{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:24:33Z","timestamp":1778721873683,"version":"3.51.4"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.virol.2024.110273","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T20:24:54Z","timestamp":1729628694000},"page":"110273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Epidemiological, diagnostic, therapeutic and prognostic impact of hepatitis B and D virus infection on hepatocellular carcinoma: A review of the literature"],"prefix":"10.1016","volume":"600","author":[{"given":"Angelo","family":"Bruni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elton","family":"Dajti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Maida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Serviddio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.01.035","article-title":"Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies","volume":"80","author":"Allweiss","year":"2024","journal-title":"J. Hepatol."},{"issue":"JUL","key":"10.1016\/j.virol.2024.110273_bib3","article-title":"Host and viral genetic variation in HBV-related hepatocellular carcinoma","volume":"9","author":"An","year":"2018","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2022.12.023","article-title":"A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis","volume":"78","author":"Anolli","year":"2023","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.virol.2024.110273_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virol.2024.110273_bib6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Artic. Lancet. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.virol.2024.110273_bib7","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.virol.2024.110273_bib8","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.febslet.2013.03.021","article-title":"Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells","volume":"587","author":"Benegiamo","year":"2013","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.virol.2024.110273_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/hep4.1564","article-title":"Hepatocellular carcinoma survival by etiology: a SEER-medicare database analysis","volume":"4","author":"Brar","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib10","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"Brunetto","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib12","article-title":"A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection","volume":"5","author":"Burm","year":"2023","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","article-title":"Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study","volume":"18","author":"Buti","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JCMA.0000000000000606","article-title":"Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: a meta-analysis","volume":"85","author":"Chang","year":"2022","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.virol.2024.110273_bib15","series-title":"\u201cHepatitis B Virus P Protein Initiates Glycolytic Bypass in HBV-Related Hepatocellular Carcinoma via a FOXO3\/miRNA-30b-5p\/MINPP1 axis\u201d","author":"Chen","year":"2021"},{"issue":"7","key":"10.1016\/j.virol.2024.110273_bib16","article-title":"A review of epidemiology and clinical relevance of Hepatitis B virus genotypes and subgenotypes","volume":"47","author":"Chen","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"9","key":"10.1016\/j.virol.2024.110273_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.10.038","article-title":"Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis","volume":"132","author":"Choi","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.10.038","article-title":"Large hepatitis delta antigen modulates transforming growth factor-\u03b2 signaling cascades: implication of hepatitis delta virus-induced liver fibrosis","volume":"132","author":"Choi","year":"2007","journal-title":"Gastroenterology"},{"issue":"Jan","key":"10.1016\/j.virol.2024.110273_bib20","article-title":"Economic impact of European liver and intestine transplantation association (ELITA) recommendations for hepatitis B prophylaxis after liver transplantation","volume":"36","author":"Cortesi","year":"2023","journal-title":"Transpl. Int."},{"key":"10.1016\/j.virol.2024.110273_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/JHC.S384751","article-title":"Molecular and clinical features of hepatocellular carcinoma in patients with HBV-HDV infection","volume":"10","author":"Costante","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/gastro\/goz023","article-title":"Hepatitis D infection: from initial discovery to current investigational therapies","volume":"7","author":"Da","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.virol.2024.110273_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104691","article-title":"The Delta-4 fibrosis score (D4FS): a novel fibrosis score in chronic hepatitis D","volume":"174","author":"Da","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110273_bib24","series-title":"\u201cRisk of Hepatocellular Carcinoma after HCV Eradication: Determining the Role of Portal Hypertension by Measuring Spleen Stiffness,\u201d","author":"Dajti","year":"2021"},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib27","article-title":"Treating hepatitis D with bulevirtide \u2013 real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.virol.2024.110273_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000847","article-title":"Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series","author":"Dietz-Fricke","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MOG.0000000000001019","article-title":"Noninvasive assessment of liver fibrosis and portal hypertension","volume":"40","author":"Duarte-Rojo","year":"2024","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.virol.2024.110273_bib30","first-page":"1","article-title":"Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: data from the ICONA cohort","volume":"00","author":"D'Arminio Monforte","year":"2023","journal-title":"Liver Int."},{"issue":"38","key":"10.1016\/j.virol.2024.110273_bib31","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D\u2019souza","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib32","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib33","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110273_bib34","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(23)00451-8","article-title":"Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta","volume":"78","author":"Etzion","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110273_bib36","author":"Fernandes da Silva"},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110273_bib38","series-title":"\u201c48 Weeks of High Dose (10 Mg) Bulevirtide as Monotherapy or with Peginterferon Alfa-2a in Patients with Chronic HBV\/HDV Co-infection,\u201d","author":"Gane","year":"2020"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/HEP.0000000000000642","article-title":"Association of hepatitis delta virus with liver morbidity and mortality: a systematic literature review and meta-analysis","volume":"79","author":"Gish","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib41","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact","volume":"34","author":"Goldstein","year":"2005","journal-title":"Int. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2022-326992","article-title":"MAFLD, HCC and the dilemma of (changing) terminology in liver diseases","volume":"72","author":"Hernaez","year":"2023","journal-title":"Gut"},{"issue":"Pt 25","key":"10.1016\/j.virol.2024.110273_bib43","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1242\/jcs.01589","article-title":"AP-1 subunits: quarrel and harmony among siblings","volume":"117","author":"Hess","year":"2004","journal-title":"J. Cell Sci."},{"issue":"Pt 25","key":"10.1016\/j.virol.2024.110273_bib44","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1242\/jcs.01589","article-title":"AP-1 subunits: quarrel and harmony among siblings","volume":"117","author":"Hess","year":"2004","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.virol.2024.110273_bib45","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jac\/dku041","article-title":"Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B","volume":"69","author":"Hsu","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"9785","key":"10.1016\/j.virol.2024.110273_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.virol.2024.110273_bib47","article-title":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep"},{"issue":"0","key":"10.1016\/j.virol.2024.110273_bib48","article-title":"Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta","volume":"0","author":"Jachs","year":"2024","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-87679-w","article-title":"Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"issue":"Sep","key":"10.1016\/j.virol.2024.110273_bib50","article-title":"HBV induced hepatocellular carcinoma and related potential immunotherapy","volume":"159","author":"Jia","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.virol.2024.110273_bib51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.gastha.2024.01.001","article-title":"Dynamics of virological and clinical response parameters of bulevirtide treatment for hepatitis D: real-world data","volume":"3","author":"Killer","year":"2024","journal-title":"Gastro Hep Advances"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0033-1345716","article-title":"Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J","volume":"33","author":"Liu","year":"2013","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib57","article-title":"TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib58","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib59","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6 Pt B","key":"10.1016\/j.virol.2024.110273_bib60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.semcancer.2013.08.006","article-title":"Possible origins and evolution of the hepatitis B virus (HBV)","volume":"23","author":"Locarnini","year":"2013","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib61","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2024.110273_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/liv.13205","article-title":"Non-invasive fibrosis score for hepatitis delta","volume":"37","author":"Lutterkort","year":"2017","journal-title":"Liver Int."},{"issue":"9","key":"10.1016\/j.virol.2024.110273_bib64","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrgastro.2012.114","article-title":"Hepatic stem cells and transforming growth factor \u03b2 in hepatocellular carcinoma","volume":"9","author":"Majumdar","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib65","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/v13020210","article-title":"Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver","volume":"13","author":"Mason","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib67","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human viral oncogenesis: a cancer hallmarks analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.virol.2024.110273_bib68","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib69","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.patbio.2009.11.002","article-title":"Vaccination des enfants contre l\u2019h\u00e9patite B: l\u2019exp\u00e9rience ta\u00efwanaise","volume":"58","author":"Ni","year":"2010","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.virol.2024.110273_bib70","series-title":"\u201cChitinase 3-like 1 Is a Profibrogenic Factor Overexpressed in the Aging Liver and in Patients with Liver Cirrhosis\u201d","author":"Nishimura","year":"2021"},{"issue":"S1","key":"10.1016\/j.virol.2024.110273_bib71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.14833","article-title":"Is hepatitis delta underestimated?","volume":"41","author":"Papatheodoridi","year":"2021","journal-title":"Liver Int."},{"issue":"S1","key":"10.1016\/j.virol.2024.110273_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/liv.15253","article-title":"Hepatocellular carcinoma: the virus or the liver?","volume":"43","author":"Papatheodoridi","year":"2023","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib73","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib74","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000252780","article-title":"Impacts of vaccination on hepatitis B viral infections in korea over a 25-year period","volume":"53","author":"Park","year":"2010","journal-title":"Intervirology"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/a-2133-8614","article-title":"Hepatitis delta infection: a clinical review","volume":"43","author":"Pearlman","year":"2023","journal-title":"Semin. Liver Dis."},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/v13030368","article-title":"HBV-integration studies in the clinic: role in the natural history of infection","volume":"13","author":"Pollicino","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib78","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigveh\u00ed","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.virol.2024.110273_bib80","article-title":"Multiple barriers impede screening for hepatitis delta: an internet-based survey of healthcare providers","author":"Rao","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib81","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib82","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","author":"Razavi-Shearer","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110273_bib83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/liv.13018","article-title":"The adventure of delta","volume":"36","author":"Rizzetto","year":"2016","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib84","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"issue":"13","key":"10.1016\/j.virol.2024.110273_bib85","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268818001942","article-title":"Hepatitis delta virus and hepatocellular carcinoma: an update","volume":"146","author":"Romeo","year":"2018","journal-title":"Epidemiol. Infect."},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib86","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.virol.2024.110273_bib87","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.virol.2024.110273_bib88","first-page":"2351","article-title":"Hepatitis D and hepatitis E","volume":"93","author":"Sakugawa","year":"2004","journal-title":"Nihon Naika Gakkai Zasshi"},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib89","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/apt.17878","article-title":"Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection","volume":"59","author":"Sandmann","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virol.2024.110273_bib90","series-title":"\u201cThe Journal of Infectious Diseases the Third Signal Cytokine Interleukin 12 rather than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-specific T Cells,\u201d","author":"Schirdewahn","year":"2016"},{"issue":"10003","key":"10.1016\/j.virol.2024.110273_bib91","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib92","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2021.09.009","article-title":"Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States","volume":"76","author":"seok Kim","year":"2022","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.virol.2024.110273_bib93","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020533","article-title":"Hepatitis virus and hepatocellular carcinoma: recent advances","volume":"15","author":"Shen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.virol.2024.110273_bib95","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/S0168-8278(23)03298-1","article-title":"Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis","volume":"78","author":"Stern","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib96","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib98","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib99","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4251\/wjgo.v16.i4.1097","article-title":"Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: where we are now","volume":"16","author":"Sukowati","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"issue":"4","key":"10.1016\/j.virol.2024.110273_bib101","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1 Suppl. l","key":"10.1016\/j.virol.2024.110273_bib102","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65213-8","article-title":"Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma","volume":"10","author":"Trung","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65213-8","article-title":"Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma","volume":"10","author":"Trung","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65213-8","article-title":"Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma","volume":"10","author":"Trung","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib106","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.virol.2024.110273_bib107","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/genes9100495","article-title":"The global hepatitis B virus genotype distribution approximated from available genotyping data","volume":"9","author":"Velkov","year":"2018","journal-title":"Genes"},{"issue":"S4","key":"10.1016\/j.virol.2024.110273_bib108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncol."},{"key":"10.1016\/j.virol.2024.110273_bib109","series-title":"Epidemiological Trends and Trajectories of MAFLD-Associated Hepatocellular Carcinoma 2002-2033: the ITA.LI.CA Database","author":"Vitale","year":"1985"},{"issue":"3","key":"10.1016\/j.virol.2024.110273_bib110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.14334","article-title":"Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B","volume":"40","author":"Voulgaris","year":"2020","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib111","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib112","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110273_bib113","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(23)00487-7","article-title":"Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study","volume":"78","author":"Wedemeyer","year":"2023","journal-title":"J. Hepatol."},{"issue":"0","key":"10.1016\/j.virol.2024.110273_bib114","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase 3 randomized trial","volume":"0","author":"Wedemeyer","year":"2024","journal-title":"J. Hepatol."},{"issue":"19","key":"10.1016\/j.virol.2024.110273_bib115","article-title":"The association between hepatitis B mutants and hepatocellular carcinoma","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine (United States)"},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2009.02.053","article-title":"A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention","volume":"286","author":"Wild","year":"2009","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.virol.2024.110273_bib117","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2893.2012.01597.x","article-title":"Large hepatitis delta antigen activates STAT-3 and NF-\u03baB via oxidative stress","volume":"19","author":"Williams","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"10","key":"10.1016\/j.virol.2024.110273_bib118","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2893.2012.01597.x","article-title":"Large hepatitis delta antigen activates STAT-3 and NF-\u03baB via oxidative stress","volume":"19","author":"Williams","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.virol.2024.110273_bib119","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.virol.2024.110273_bib120","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.virol.2024.110273_bib121","series-title":"\u201cMicroarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma,\u201d","author":"Yu","year":"2021"},{"issue":"34","key":"10.1016\/j.virol.2024.110273_bib122","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.virol.2024.110273_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/v12111334","article-title":"Interplay between hepatitis D virus and the interferon response","volume":"12","author":"Zhang","year":"2020","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.virol.2024.110273_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.177","article-title":"Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma","volume":"49","author":"Zhang","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"17","key":"10.1016\/j.virol.2024.110273_bib125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02120-17","article-title":"\u201c CD8 + T-cell response-associated evolution of hepatitis B virus core protein and disease progress ,\u201d","volume":"92","author":"Zhang","year":"2018","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2024.110273_bib126","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41388-020-01593-5","article-title":"C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.virol.2024.110273_bib127","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/liv.15408","article-title":"Real-life experiences with bulevirtide for the treatment of hepatitis delta\u201448 weeks data from a German centre","volume":"42","author":"Z\u00f6llner","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.virol.2024.110273_bib128","unstructured":"Hepatitis B.\u201d Accessed: September. 1, 2024. [Online]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:36:10Z","timestamp":1764599770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224002940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":128,"alternative-id":["S0042682224002940"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110273","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological, diagnostic, therapeutic and prognostic impact of hepatitis B and D virus infection on hepatocellular carcinoma: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110273"}}